Advanced search
Publication Cover
Current Medical Research and Opinion Volume 22, 2006 - Issue 7
Submit an article Journal homepage
180
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies

Steven S. Smugar Merck & Co., Inc., West Point, PA, USACorrespondence[email protected]
,
Thomas J. Schnitzer Northwestern University School of Medicine, Chicago, IL, USA
,
Arthur L. Weaver University of Nebraska Medical Center, Omaha, NE, USA
,
Bernard R. Rubin University of North Texas, Fort Worth, TX, USA
,
Adam B. Polis Merck & Co., Inc., West Point, PA, USA
&
Andrew M. Tershakovec Merck & Co., Inc., West Point, PA, USA
Pages 1353-1367 | Accepted 12 Apr 2006, Published online: 08 Jun 2006

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.